top of page

R&D Pipeline

FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD), chemotherapy induced anemia (CIA), Duchenne muscular dystrophy (DMD), and locally advanced pancreatic cancer. The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.

HIF Platform

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ROXADUSTAT (HIF-PHI) ANEMIA OF CKD*

Approved

Phase 3

China

ROXADUSTAT (HIF-PHI) ANEMIA IN CIA

EVRENZO   ,  爱瑞卓

TM

®

*Currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and patients not on dialysis.

PARTNERED

Fibrotic Disease Platform

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Phase 2

Locally Advanced Pancreatic Cancer

Duchenne Muscular Dystrophy

PAMREVLUMAB
(ANTI-CTGF ANTIBODY)

Phase 3

Phase 3

WHOLLY-OWNED

Early Development 
Pipeline

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Phase 3

Additional Programs
Various Indications

FG-3165

(ANTI-GAL-9 ANTIBODY) 

Solid Tumors/AML

FG-3175

(ANTI-CCR8 ANTIBODY)

Solid Tumors

FG-3246 (FOR46)

(CD46-TARGETING ADC)

Metastatic Castration-Resistant
Prostate Cancer (mCRPC)

Phase 1

Preclinical

Preclinical

Preclinical

IN LICENSED

WHOLLY-OWNED

Pamrevlumab

Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.

Roxadustat

Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin.

Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.

bottom of page